Skip to main content
Top
Published in: Medical Oncology 12/2014

01-12-2014 | Original Paper

Upregulation of PDK1 associates with poor prognosis in esophageal squamous cell carcinoma with facilitating tumorigenicity in vitro

Authors: Zhonglu Yang, Zhiyi Wu, Tao Liu, Lei Han, Chunhui Wang, Bo Yang, Fei Zheng

Published in: Medical Oncology | Issue 12/2014

Login to get access

Abstract

3-Phosphoinositide-dependent protein kinase-1 (PDK1) has been reported to be closely correlated with proliferation, apoptosis and invasion of esophageal cancer cells. However, its expression pattern and clinical significance in human esophageal squamous cell carcinoma (ESCC) remain unclear. To address this problem, immunohistochemistry was performed to detect the expression and the subcellular localization of PDK1 protein in 120 paired of formalin-fixed and paraffin-embedded cancerous and adjacent non-cancerous tissues. Then, its associations with tumor progression and patients’ prognosis were statistically evaluated. After that, we performed migration and invasion assays of siRNA-targeted PDK1-transfected cells in vitro. As a result, immunohistochemistry analysis showed that the PDK1 protein was expressed in cytoplasm of the carcinoma cells in ESCC tissues, but not expressed in adjacent non-cancerous tissues. Statistical analysis indicated that the expression level of PDK1 protein in ESCC tissues was significantly higher than those in adjacent non-cancerous tissues (P < 0.001). In addition, high PDK1 expression was found to be closely correlated with advanced tumor stage (P = 0.006), positive lymph node metastasis (P = 0.01) and high histological grade (P = 0.02). Moreover, survival analysis revealed that PDK1 overexpression was significantly associated with shorter overall survival (P = 0.001). The multivariate analysis further identified PDK1 expression as an independent prognostic factor for ESCC patients. In ESCC cell lines, the knockdown of PDK1 using siRNA inhibited the cell migration and invasion in vitro. These findings support that PDK1 may contribute to the aggressive progression of ESCC. Of note, PDK1 may serve as an effective prognostic marker and provide a novel therapeutic strategy against human ESCC.
Literature
1.
3.
4.
go back to reference Shang L, Wang M. Molecular alterations and clinical relevance in esophageal squamous cell carcinoma. Front Med. 2013;7:401–10.PubMedCrossRef Shang L, Wang M. Molecular alterations and clinical relevance in esophageal squamous cell carcinoma. Front Med. 2013;7:401–10.PubMedCrossRef
5.
go back to reference Lehrbach DM, Nita ME, Cecconello I. Molecular aspects of esophageal squamous cell carcinoma carcinogenesis. Arq Gastroenterol. 2003;40:256–61.PubMedCrossRef Lehrbach DM, Nita ME, Cecconello I. Molecular aspects of esophageal squamous cell carcinoma carcinogenesis. Arq Gastroenterol. 2003;40:256–61.PubMedCrossRef
6.
go back to reference Calleja V, Laguerre M, de Las Heras-Martinez G, Parker PJ, Requejo-Isidro J, Larijani B. Acute regulation of PDK1 by a complex interplay of molecular switches. Biochem Soc Trans. 2014;42:1435–40.PubMedCrossRef Calleja V, Laguerre M, de Las Heras-Martinez G, Parker PJ, Requejo-Isidro J, Larijani B. Acute regulation of PDK1 by a complex interplay of molecular switches. Biochem Soc Trans. 2014;42:1435–40.PubMedCrossRef
7.
go back to reference Ohtsubo K, Yamada T, Zhao L, Jin TF, Takeuchi S, Mouri H, Yamashita K, Yasumoto K, Fujita N, Kitagawa H, Ohta T, Ikeda H, Yano S. Expression of Akt kinase-interacting protein 1, a scaffold protein of the PI3 K/PDK1/Akt pathway, in pancreatic cancer. Pancreas. 2014;43:1093–100.PubMedCrossRef Ohtsubo K, Yamada T, Zhao L, Jin TF, Takeuchi S, Mouri H, Yamashita K, Yasumoto K, Fujita N, Kitagawa H, Ohta T, Ikeda H, Yano S. Expression of Akt kinase-interacting protein 1, a scaffold protein of the PI3 K/PDK1/Akt pathway, in pancreatic cancer. Pancreas. 2014;43:1093–100.PubMedCrossRef
8.
go back to reference Zhou J, Song S, He S, Zhu X, Zhang Y, Yi B, Zhang B, Qin G, Li D. MicroRNA-375 targets PDK1 in pancreatic carcinoma and suppresses cell growth through the Akt signaling pathway. Int J Mol Med. 2014;33:950–6.PubMed Zhou J, Song S, He S, Zhu X, Zhang Y, Yi B, Zhang B, Qin G, Li D. MicroRNA-375 targets PDK1 in pancreatic carcinoma and suppresses cell growth through the Akt signaling pathway. Int J Mol Med. 2014;33:950–6.PubMed
9.
go back to reference Pal D, Outram SP, Basu A. Upregulation of PKCη by PKCε and PDK1 involves two distinct mechanisms and promotes breast cancer cell survival. Biochim Biophys Acta. 2013;1830:4040–5.PubMedCentralPubMedCrossRef Pal D, Outram SP, Basu A. Upregulation of PKCη by PKCε and PDK1 involves two distinct mechanisms and promotes breast cancer cell survival. Biochim Biophys Acta. 2013;1830:4040–5.PubMedCentralPubMedCrossRef
10.
go back to reference Han L, Zhang G, Zhang N, Li H, Liu Y, Fu A, Zheng Y. Prognostic potential of microRNA-138 and its target mRNA PDK1 in sera for patients with non-small cell lung cancer. Med Oncol. 2014;31:129.PubMedCrossRef Han L, Zhang G, Zhang N, Li H, Liu Y, Fu A, Zheng Y. Prognostic potential of microRNA-138 and its target mRNA PDK1 in sera for patients with non-small cell lung cancer. Med Oncol. 2014;31:129.PubMedCrossRef
11.
go back to reference Yu J, Chen KS, Li YN, Yang J, Zhao L. Silencing of PDK1 gene expression by RNA interference suppresses growth of esophageal cancer. Asian Pac J Cancer Prev. 2012;13:4147–51.PubMedCrossRef Yu J, Chen KS, Li YN, Yang J, Zhao L. Silencing of PDK1 gene expression by RNA interference suppresses growth of esophageal cancer. Asian Pac J Cancer Prev. 2012;13:4147–51.PubMedCrossRef
12.
go back to reference Chen MQ, Xu BH, Zhang YY. Analysis of prognostic factors for esophageal squamous cell carcinoma with distant organ metastasis at initial diagnosis. J Chin Med Assoc. 2014 (in press). Chen MQ, Xu BH, Zhang YY. Analysis of prognostic factors for esophageal squamous cell carcinoma with distant organ metastasis at initial diagnosis. J Chin Med Assoc. 2014 (in press).
13.
go back to reference Fischer EH. Cellular regulation by protein phosphorylation. Biochem Biophys Res Commun. 2013;430:865–7.PubMedCrossRef Fischer EH. Cellular regulation by protein phosphorylation. Biochem Biophys Res Commun. 2013;430:865–7.PubMedCrossRef
14.
go back to reference Najafov A, Shpiro N, Alessi DR. Akt is efficiently activated by PIF-pocket- and PtdIns(3,4,5)P3-dependent mechanisms leading to resistance to PDK1 inhibitors. Biochem J. 2012;448:285–95.PubMedCrossRef Najafov A, Shpiro N, Alessi DR. Akt is efficiently activated by PIF-pocket- and PtdIns(3,4,5)P3-dependent mechanisms leading to resistance to PDK1 inhibitors. Biochem J. 2012;448:285–95.PubMedCrossRef
17.
go back to reference Bayascas JR, Leslie NR, Parsons R, Fleming S, Alessi DR. Hypomorphic mutation of PDK1 suppresses tumorigenesis in PTEN(±) mice. Curr Biol. 2005;15:1839–46.PubMedCrossRef Bayascas JR, Leslie NR, Parsons R, Fleming S, Alessi DR. Hypomorphic mutation of PDK1 suppresses tumorigenesis in PTEN(±) mice. Curr Biol. 2005;15:1839–46.PubMedCrossRef
18.
go back to reference Zabkiewicz J, Pearn L, Hills RK, Morgan RG, Tonks A, Burnett AK, Darley RL. The PDK1 master kinase is over-expressed in acute myeloid leukemia and promotes PKC-mediated survival of leukemic blasts. Haematologica. 2014;99:858–64.PubMedCentralPubMedCrossRef Zabkiewicz J, Pearn L, Hills RK, Morgan RG, Tonks A, Burnett AK, Darley RL. The PDK1 master kinase is over-expressed in acute myeloid leukemia and promotes PKC-mediated survival of leukemic blasts. Haematologica. 2014;99:858–64.PubMedCentralPubMedCrossRef
19.
go back to reference Zeng X, Xu H, Glazer RI. Transformation of mammary epithelial cells by 3-phosphoinositide-dependent protein kinase-1 (PDK1) is associated with the induction of protein kinase Calpha. Cancer Res. 2002;62:3538–43.PubMed Zeng X, Xu H, Glazer RI. Transformation of mammary epithelial cells by 3-phosphoinositide-dependent protein kinase-1 (PDK1) is associated with the induction of protein kinase Calpha. Cancer Res. 2002;62:3538–43.PubMed
20.
go back to reference Fujiwara S, Kawano Y, Yuki H, Okuno Y, Nosaka K, Mitsuya H, Hata H. PDK1 inhibition is a novel therapeutic target in multiple myeloma. Br J Cancer. 2013;108:170–8.PubMedCentralPubMedCrossRef Fujiwara S, Kawano Y, Yuki H, Okuno Y, Nosaka K, Mitsuya H, Hata H. PDK1 inhibition is a novel therapeutic target in multiple myeloma. Br J Cancer. 2013;108:170–8.PubMedCentralPubMedCrossRef
21.
go back to reference Bhola NE, Freilino ML, Joyce SC, Sen M, Thomas SM, Sahu A, Cassell A, Chen CS, Grandis JR. Antitumor mechanisms of targeting the PDK1 pathway in head and neck cancer. Mol Cancer Ther. 2012;11:1236–46.PubMedCentralPubMedCrossRef Bhola NE, Freilino ML, Joyce SC, Sen M, Thomas SM, Sahu A, Cassell A, Chen CS, Grandis JR. Antitumor mechanisms of targeting the PDK1 pathway in head and neck cancer. Mol Cancer Ther. 2012;11:1236–46.PubMedCentralPubMedCrossRef
23.
go back to reference Slattery ML, Lundgreen A, Herrick JS, Wolff RK. Genetic variation in RPS6KA1, RPS6KA2, RPS6KB1, RPS6KB2, and PDK1 and risk of colon or rectal cancer. Mutat Res. 2011;706:13–20.PubMedCentralPubMedCrossRef Slattery ML, Lundgreen A, Herrick JS, Wolff RK. Genetic variation in RPS6KA1, RPS6KA2, RPS6KB1, RPS6KB2, and PDK1 and risk of colon or rectal cancer. Mutat Res. 2011;706:13–20.PubMedCentralPubMedCrossRef
Metadata
Title
Upregulation of PDK1 associates with poor prognosis in esophageal squamous cell carcinoma with facilitating tumorigenicity in vitro
Authors
Zhonglu Yang
Zhiyi Wu
Tao Liu
Lei Han
Chunhui Wang
Bo Yang
Fei Zheng
Publication date
01-12-2014
Publisher
Springer US
Published in
Medical Oncology / Issue 12/2014
Print ISSN: 1357-0560
Electronic ISSN: 1559-131X
DOI
https://doi.org/10.1007/s12032-014-0337-5

Other articles of this Issue 12/2014

Medical Oncology 12/2014 Go to the issue
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.